“r.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
By Roxanne Liu and Tony Munroe
BEIJING (Reuters) – About 90% of Workers at Sinovac Biotech Ltd and their families have taken an experimental coronavirus vaccine developed by the Chinese company as a component of the country’s emergency use program, its executive leader said Sunday.
The scope of vaccines under the emergency programme, which China introduced in July but published few details, shows how actively it is using experimental vaccines in the hope of protecting essential personnel from a consurgent resurgence of COVID-19, even though trials are still ongoing.
The program is aimed at express groups, adding medical bodies of workers and those operating in food markets and in the transport and services sectors.
Sinovac, whose CoronaVac is in phase 3 clinical trials and is included in the emergency program, presented the candidate vaccine to about 2,000 to 3,000 workers and their families voluntarily, CEO Yin Weidong told Reuters.
“As a vaccine developer and manufacturer, a new outbreak can have a direct effect on our vaccine production,” Yin said outside of an exhibition of foreign industry in Beijing, explaining why his company was included in the emergency program.
The knowledge collected under the program may simply provide evidence of the safety of the vaccine, however this knowledge, which is not a component of the registered clinical trial protocols, will not be used as the number one tissue that regulators are reviewing for. pass judgment on approval of the vaccine for advertising. purposes, Yin told me.
He stated that those who had selected to be vaccinated, adding to his wife and parents, had been informed of possible side effects before taking the vaccine and that their vaccine was only completing early and intermediate trials.
Yin, who also took the photo, said doctors had asked them about their fitness before vaccination and that the rate of adverse reactions among other vaccinated people was “very low.”
Side effects after taking CoronaVac come with fatigue, fever and pain, with more commonly mild symptoms, depending on the effects of a mid-term trial sponsored through Sinovac, which involved six hundred participants and published last month before peer review.
No vaccine has passed large-scale final tests to show that it is effective enough and protect others from the virus that has caused more than 870,000 deaths worldwide.
(Corrects a typo in the paragraph)
(Information through Roxanne Liu and Tony Munroe; Editing through Miyoung Kim and William Mallard)